AMT Provides Business Update for the Third Quarter 2010

AMSTERDAM, November 18, 2010 - Amsterdam Molecular Therapeutics (EuroNext Amsterdam: AMT), a
leader in the field of human gene therapy, today provides its non-audited
business update in compliance with the EU transparency directive. This report
summarizes material events and AMT's financial position for the third quarter
of 2010.

Q3 2010 Highlights

    - Glybera(R):

    - Responses to Day 120 questions of the EMA/CHMP will be
      submitted on schedule

    - EMA formal review of dossier remains on track for 2011
      decision.

    - Successful fund raising of EUR14.3 million in new equity

    - Progression of Hemophilia B Phase I/II study with partner St
      Jude Children's Research Hospital

    - microRNA: silencing gene therapy technology achieves 80%
      cholesterol reduction with activity limited only to the targeted
      hepatocytes

    - Supervisory Board strengthened through addition of 3 new industry
      professionals

    - Key financial figures in line with guidance

    - Cash & cash equivalents of EUR 10.1 million at September 30,
      2010; equivalent to EUR 23.2 million on a pro forma basis after including
      the net proceeds of the October 2010 fund raising

Business Update

AMT's cash position* on September 30, 2010 amounted to EUR
10.1 million compared to EUR 13.5 million on June 30, 2010. The cash outflow
in the third quarter of 2010, amounting to EUR 3.4 million, compared to EUR
3.6 million in the prior year, mainly represented operational cash flow. AMT
employed 84 persons as of September 30, 2010. Total expenses in the third
quarter of 2010 were EUR 4.7 million compared to EUR 4.4 million in the same
period last year.

*The Company's cash position is composed of cash and cash
equivalents.

Material events after September 30, 2010

On October 6, 2010, the Company announced that it had
successfully raised EUR 14.3 million, before expenses, through an issue of
8.4 million new ordinary shares, which were placed at a price of EUR 1.70 per
share, with investors and management. Following this issue and net of
expenses, AMT would have had pro forma cash at 30 September 2010 amounting to
EUR 23.2 million and 23,504,022 shares in issue. As a consequence of the
issue, and in accordance with its terms, the conversion price of the
convertible loan stock issued in December 2009 was reduced from EUR 3.91 per
share to EUR 3.69 per share.

About Amsterdam Molecular Therapeutics

AMT is a leader in the development of human gene based
therapies. Using adeno-associated viral (AAV) derived vectors as the delivery
vehicle of choice for therapeutic genes, the company has been able to design
and validate what is probably the first stable and scalable AAV production
platform. This proprietary platform can be applied to a large number of rare
(orphan) diseases that are caused by one faulty gene. Currently, AMT has a
product pipeline with several AAV-based gene therapy products in LPLD,
Hemophilia B, Duchenne Muscular Dystrophy, Acute Intermittent Porphyria, and
Parkinson's Disease at different stages of research or development. AMT was
founded in 1998 and is based in Amsterdam.

Certain statements in this press release are "forward-looking statements"
including those that refer to management's plans and expectations for future
operations, prospects and financial condition. Words such as "strategy,"
"expects," "plans," "anticipates," "believes," "will," "continues,"
"estimates," "intends," "projects," "goals," "targets" and other words of
similar meaning are intended to identify such forward-looking statements.
Such statements are based on the current expectations of the management of
AMT only. Undue reliance should not be placed on these statements because, by
their nature, they are subject to known and unknown risks and can be affected
by factors that are beyond the control of AMT. Actual results could differ
materially from current expectations due to a number of factors and
uncertainties affecting AMT's business. AMT expressly disclaims any intent or
obligation to update any forward-looking statements herein except as required
by law.

PRN NLD

For further enquiries: Jorn Aldag, CEO, AMT, Tel : +31-20-566-7394, j.aldag at amtbiopharma.com; Mike Sinclair, Partner, Halsin Partners, Tel : +44-20-7318-2955, msinclair at halsin.com